Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

January 5, 2023

https://www.globenewswire.com/news-release/2023/01/05/2583538/0/en/Landos-Biopharma-Provides-Comprehensive-Update-on-Clinical-Development-Plans.html

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis

On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024

Read more at globenewswire.com

Related news for (LABP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.